Analysis of 6-week mortality and influencing factors in patients with liver cirrhosis and portal vein thrombosis complicated by acute gastrointestinal bleeding.

The 6-week mortality rate in patients with liver cirrhosis and portal vein thrombosis complicated by acute gastrointestinal bleeding was approximately 14.7%.

• 232 patients with liver cirrhosis and portal vein thrombosis complicated by acute gastrointestinal bleeding were included in the retrospective study.
• Patients were admitted to West China Hospital of Sichuan University from January 1, 2020 to November 30, 2022.
• 34 patients were classified in the mortality group and 198 in the non-mortality group.
• 75 of the 232 patients had their first bleeding episode.

Elevated ALP levels were independently associated with 6-week mortality in patients with liver cirrhosis and portal vein thrombosis complicated by acute gastrointestinal bleeding.

• Multivariate logistic regression analysis identified elevated ALP as an independent risk factor.
• OR = 1.01, 95% CI (1.01, 1.01), p < 0.01.
• ALP showed a statistically significant difference between the mortality and non-mortality groups (p < 0.05).

5-day treatment failure was independently associated with 6-week mortality in patients with liver cirrhosis and portal vein thrombosis complicated by acute gastrointestinal bleeding.

• Multivariate logistic regression analysis identified 5-day treatment failure as an independent risk factor.
• OR = 11.27, 95% CI (3.45, 36.81), p < 0.01.
• The overall 5-day treatment failure rate in the cohort was 8.62%.
• 5-day treatment failure showed a statistically significant difference between the mortality and non-mortality groups (p < 0.05).

Numerous laboratory and clinical variables differed significantly between the mortality and non-mortality groups.

• Significant differences were found in etiology of liver cirrhosis, presence of HCC, TBiL, ALT, BUN, Na, eGFR, DBiL, AST, GGT, ALP, CR, WBC, PLT, and PT (all p < 0.05).
• These differences were identified through comparison of baseline general information, laboratory indicators, and other clinical data.
• Variables were compared between the mortality group (n = 34) and the non-mortality group (n = 198).